Alloy Therapeutics utilizes a high-efficiency CAR discovery and screening workflow that integrates the ATX-Gx™ humanized mouse platform with rapid cell-based functional assays to accelerate the identification of potent Chimeric Antigen Receptor (CAR) candidates. This streamlined approach enables researchers to optimize binder selection and validate CAR-T efficacy early in the drug development process to reduce timelines for oncology therapeutics.
Chimeric antigen receptor cell therapy (CAR-T, CAR-NK, etc.) is a promising therapeutic modality, but functional screening is a bottleneck for traditional two-step CAR-T discovery process of antibody binder discovery and CAR-T functional engineering. In this webinar, scientists at Alloy showcase their unique CAR discovery workflow that incorporates human antibody identification and characterization, mRNA-based CAR construct generation, and in vitro and in vivo functional screening. Learn from the discovery scientists that helm this process and help cell therapy companies and discovery teams identify functional chimeric antigen receptors three months faster than conventional approaches.